查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1470864

非何杰金氏淋巴瘤治疗市场：按治疗类型、应用和最终用户划分 - 全球预测 2024-2030

Non-Hodgkin Lymphoma Treatment Market by Treatment Type (Chemotherapy, Immunotherapy, Radiation Therapy), Application (Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma), End-User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年非何杰金氏淋巴瘤治疗市场规模为82亿美元，预计2024年将达88.4亿美元，2030年将达到139.8亿美元，复合年增长率为7.91%。

非何杰金氏淋巴瘤是一种始于淋巴结和胃、肠等器官组织的癌症。颈部淋巴结肿大、腹部疼痛或肿胀、胸痛、咳嗽和呼吸困难是此疾病的常见症状。非何杰金氏淋巴瘤(NHL) 的治疗方法包括化疗、放射线治疗、标靶治疗血浆置换和干细胞移植。非何杰金氏淋巴瘤的新治疗方法着重于开发个人化药物、标靶药物和特异性攻击癌细胞的免疫疗法。生活方式的改变和肥胖的增加导致患有癌症和肿瘤的患者人数迅速增加。此外，有前景的淋巴瘤药物上市和药物核准数量正在迅速增加。然而，获得癌症治疗方案的高昂成本降低了治疗方案的可近性。此外，对癌症治疗选择的严格规定限制了研究机构对癌症治疗研究的投资，并阻碍了新药的商业化。政府专注于提高人们对癌症及其治疗方法的认识，有助于减少复杂法规所带来的障碍。生物技术和製药机构和公司正在引入针对癌症的生物疗法和药物选择，包括抗体药物复合体和蛋白酶体抑制剂。

主要市场统计
基准年[2023] 82亿美元
预测年份 [2024] 88.4亿美元
预测年份 [2030] 139.8亿美元
复合年增长率（%） 7.91%

治疗类型化疗可防止癌症扩散到身体其他部位

化疗可以阻止癌细胞分裂和增殖，从而防止癌症进展。化疗可以直接注射到静脉（静脉化疗）、锭剂或两者的组合。此外，一些化疗药物可能会引起痛苦的副作用，例如肌肉和关节疼痛、头痛和胃痛。免疫疗法也是一种癌症治疗方法，它利用患者身体的免疫系统来破坏癌细胞，并使用称为单株或双特异性抗体的抗体来靶向它们。放射线治疗使用强大的能量束（通常是 X 射线）来杀死癌细胞。外部放射线治疗是非非何杰金氏淋巴瘤最常用的治疗方法。干细胞移植是治疗方法。标靶治疗是指使用化学製剂特异性辨识和攻击特定癌细胞的癌症治疗方法。标靶治疗可以单独用作治疗选择，也可以与其他治疗方法（例如常规标准化疗和放射线治疗）结合使用。

应用实例：免疫治疗与放射线治疗相结合治疗晚期瀰漫性大B细胞淋巴瘤（DLBCL）

瀰漫性大 B 细胞淋巴瘤 (DLBCL) 是一种非何杰金氏淋巴瘤(NHL)，当患者体内产生异常 B 淋巴细胞并快速增殖时就会发生这种情况。治疗策略包括合併药物化疗和单株抗体治疗。滤泡性淋巴瘤是一种低度非何恶性非何杰金氏淋巴瘤(NHL)，当白血球聚集在淋巴腺或器官时就会发生。放射线治疗、化疗和免疫疗法是常见的治疗方法。套细胞淋巴瘤 (MCL) 是一种侵袭性且罕见的非何杰金氏淋巴瘤(NHL)，影响淋巴结的套区。化疗药物和免疫疗法通常用于治疗这些癌症。

最终用户医院更采用非何杰金氏淋巴瘤治疗新策略

医院正在迅速引入免疫疗法和化疗来治疗非何杰金氏淋巴瘤。我们也投资开发不需要在医院过夜的新治疗方法。癌症中心是一个开发尖端研究活动中产生的科学知识并将其转化为针对癌症患者的有前景的实验室治疗方法的机构。居家照护服务允许患者在自己的家中接受治疗和护理，这对于老年患者和有特殊需求的患者尤其有利。居家照护服务包括为患者復健提供的各种医疗、社会和復健服务。

区域洞察

美国和加拿大等美洲主要国家对癌症治疗的治疗方案和报销制度的认知度较高。美洲非何杰金氏淋巴瘤治疗市场受到该地区癌症治疗中心和肿瘤科医师数量不断增加的推动。此外，美洲国家的特点是拥有大型生物技术和製药公司，并推出了多种非何杰金氏淋巴瘤治疗方案。包括中国在内的亚洲国家正致力于增加抗癌药物的核准数量。各国政府正迅速集中精力提高人们对淋巴瘤及其症状的认识。欧洲国家建立了学术研究机构，并积极参与非何杰金氏淋巴瘤和其他癌症的相关研发活动。此外，临床试验的增加以及生物技术公司和政府之间的合作是引入新治疗方法的重要驱动力。

FPNV定位矩阵

FPNV定位矩阵对于评估非何杰金氏淋巴瘤治疗市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对非何杰金氏淋巴瘤治疗市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告在以下方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4. 竞争评估和情报：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况和製造能力进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1.非何杰金氏淋巴瘤治疗市场的市场规模与预测是多少？

2.在非何杰金氏淋巴瘤治疗市场的预测期内，有哪些产品、细分市场、应用和领域需要考虑投资？

3.非何杰金氏淋巴瘤治疗市场的技术趋势与法规结构是什么？

4.非何杰金氏淋巴瘤治疗市场主要供应商的市场占有率是多少？

5. 进入非何杰金氏淋巴瘤治疗市场的合适业态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 非何杰金氏淋巴瘤发生率上升
      • 有希望的淋巴瘤药物上市和药物核准
      • 在一线治疗计划中强调 NHL 患者预后和护理标准
    • 抑制因素
      • 治疗费用昂贵且有副作用
    • 机会
      • 加大疾病治疗药物的研发力度
      • 政府和非营利组织增加投资
    • 任务
      • 对癌症治疗方案的严格规定
  • 市场区隔分析
    • 治疗类型：化疗以防止癌症扩散到身体其他部位
    • 应用：免疫疗法和放射疗法在瀰漫性大 B 细胞淋巴瘤 (DLBCL) 的晚期治疗中的应用
    • 最终用户：医院越来越多地采用 NHL 治疗新策略
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章非何杰金氏淋巴瘤治疗市场：依治疗类型

  • 化疗
  • 免疫疗法
  • 放射治疗
  • 干细胞移植
  • 标靶治疗

第七章非何杰金氏淋巴瘤治疗市场：依应用分类

  • 瀰漫性大B细胞淋巴瘤
  • 滤泡性淋巴瘤
  • 套细胞淋巴瘤

第八章非何杰金氏淋巴瘤治疗市场：依最终用户分类

  • 癌症中心
  • 居家护理
  • 医院

第九章美洲非何杰金氏淋巴瘤治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太非何非何杰金氏淋巴瘤治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲非何杰金氏淋巴瘤治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • EPKINLY (epcolitamab-bysp) 获得美国FDA核准，成为第一个也是唯一一个用于治疗成人復发性或难治性瀰漫性大 B 细胞淋巴瘤 (DLBCL) 患者的双特异性抗体
    • 杨森与 Cellular Biomedicine Group 签订全球合作与授权合约，开发下一代 CAR-T 疗法
    • 作为抗 CD20 合作的一部分，百健 (Biogen) 与基因泰克 (Genentech) 同意就后期双特异性抗体的潜在商业化收取特许权使用费
  • 战略分析和建议

第13章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-036C5CF3B518

[185 Pages Report] The Non-Hodgkin Lymphoma Treatment Market size was estimated at USD 8.20 billion in 2023 and expected to reach USD 8.84 billion in 2024, at a CAGR 7.91% to reach USD 13.98 billion by 2030.

Non-Hodgkin Lymphoma refers to a type of cancer that begins and develops in the lymph nodes and lymphatic tissue found in organs, including the stomach and intestines. Swollen lymph nodes in the neck, abdominal pain or swelling, chest pain, coughing, or trouble breathing are some common symptoms of the disease. Treatment options for non-Hodgkin lymphoma (NHL) include chemotherapy, radiation, plasmapheresis targeted therapy, and stem cell transplant. Newer treatment options for non-Hodgkin lymphoma are focused on making personalized medications, targeted drugs, and immunotherapy engineered to attack cancer cells specifically. Changing lifestyles and rising incidences of obesity have led to a surge in the number of patients suffering from cancers and tumors. Additionally, the launch of promising drugs and the number of drug approvals for lymphomas is rapidly increasing. However, the high cost of availing cancer treatment options reduces the accessibility of treatment options. Furthermore, stringent regulations for cancer treatment options have dissuaded research institutions from investing in cancer treatment research and have hampered the commercialization of novel drugs. The government's focus on increasing awareness about cancer and its treatment options is gaining traction and can aid in reducing the number of barriers posed by complex regulations. Biotechnology, and pharmaceutical institutions and companies have introduced targeted biological therapies and drug options for cancer, such as antibody-drug conjugate and proteasome inhibitors.

KEY MARKET STATISTICS
Base Year [2023] USD 8.20 billion
Estimated Year [2024] USD 8.84 billion
Forecast Year [2030] USD 13.98 billion
CAGR (%) 7.91%

Treatment type: Chemotherapy treatments to prevent the spread of cancer to other parts of the body

Chemotherapy prevents the division and growth of cancer cells, thereby preventing the progression of cancers. It is provided through a drip directly into the vein (intravenous chemotherapy), as tablets or a combination of both. Besides, some chemotherapy drugs can cause painful side effects, such as aching in the muscles and joints, headaches and stomach pains. Immunotherapy is another type of cancer treatment that uses the patient's body's immune system to destroy cancer cells and uses antibodies, monoclonal or bispecific antibodies, to target cancer cells. Radiation therapy uses rays of intense energy, often X-rays, to kill cancer cells. External radiation therapy is the most commonly used treatment strategy for NHL). Stem cell transplants are procedures that are used to replace cancerous, damaged stem cells with healthy ones. Targeted therapy refers to cancer treatment that utilizes chemical drugs to specifically identify and attack certain cancer cells. Targeted therapy can be used as a treatment option in itself or in combination with other treatments, such as traditional or standard chemotherapy or radiation therapy.

Application: Utilization of immunotherapy and radiation in advanced stages treatment of diffuse large B cell lymphoma (DLBCL)

Diffuse large B cell lymphoma (DLBCL) refers to a type of non-Hodgkin lymphoma (NHL) that starts developing when the patient's body makes abnormal B lymphocytes and proliferates quickly. The treatment strategies used include chemotherapy in combination with drugs or treatment with plus monoclonal antibodies. Follicular lymphoma refers to a type of low-grade non-Hodgkin lymphoma (NHL) that is formed due to the clustering of white blood cells in the lymph glands or organs. Radiation, immunochemotherapy, and immunotherapy are commonly used treatment options. Mantle Cell lymphoma (MCL) is an aggressive, rare form of non-Hodgkin lymphoma (NHL) that affects the mantle zone of the lymph node. Often, chemotherapy drugs and immunotherapy are used to treat such cancers.

End-user: Increasing adoption of novel strategies for NHL treatment in hospitals

Hospitals are rapidly adopting immunotherapies and chemotherapies for the treatment of NHL. They are also investing in the development of novel therapies that don't require an overnight stay in hospitals. Cancer centers refer to institutions that develop and translate scientific knowledge generated from the latest research activities into promising laboratory treatments for cancer patients. Home care services allow a patient to acquire treatment and care from their own homes and is specifically advantageous for elderly patients and patients with special needs. Home care services involve a range of health, social, and rehabilitative services for the recovery of patients.

Regional Insights

Significant Americas countries, such as the USA and Canada, are associated with a higher awareness of the availability of treatment options and reimbursement plans for cancer treatment. The Americas market for NHL treatment is driven by the increasing number of cancer care centers and oncology specialists in the region. Additionally, Americas countries are characterized by the presence of major biotechnology and pharmaceutical companies and a large number of treatment solutions introduced for Non hodgkin lymphoma. Countries in Asia, including China, have expanded their focus on increasing the number of drug approvals for cancer treatment. Governments are rapidly investing their efforts to improve awareness of lymphomas and their symptoms. European nations have well-established academic and research institutions that are actively involved in research and development activities concerning non-Hodgkin lymphoma and other cancers. Additionally, the growing number of clinical trials and collaborations between biotechnology companies and governments has been a significant driving factor towards the introduction of novel treatment therapies.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Non-Hodgkin Lymphoma Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Non-Hodgkin Lymphoma Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Non-Hodgkin Lymphoma Treatment Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, Aurobindo Pharma, Bayer AG, Cipla Inc., Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline PLC, Hetero Drugs Ltd., Hikma Pharmaceuticals PLC, Intas Pharmaceuticals Ltd., Janssen Global Services, LLC, Kyowa Kirin Co., Ltd., Lupin Ltd., Merck KGaA, Nordic Nanovector ASA by Thor Medical, Novartis AG, Pharmacyclics, LLC, Salvavidas Pharmaceutical Pvt. Ltd., Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Zydus Pharmaceuticals.

Market Segmentation & Coverage

This research report categorizes the Non-Hodgkin Lymphoma Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Treatment Type
    • Chemotherapy
    • Immunotherapy
    • Radiation Therapy
    • Stem Cell Transplantation
    • Targeted Therapy
  • Application
    • Diffuse Large B-cell Lymphoma
    • Follicular Lymphoma
    • Mantle Cell Lymphoma
  • End-User
    • Cancer Centers
    • Home Care
    • Hospitals
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Non-Hodgkin Lymphoma Treatment Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Non-Hodgkin Lymphoma Treatment Market?

3. What are the technology trends and regulatory frameworks in the Non-Hodgkin Lymphoma Treatment Market?

4. What is the market share of the leading vendors in the Non-Hodgkin Lymphoma Treatment Market?

5. Which modes and strategic moves are suitable for entering the Non-Hodgkin Lymphoma Treatment Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of non-Hodgkin lymphoma disease
      • 5.1.1.2. The launch of promising drugs and drug approval for lymphomas
      • 5.1.1.3. Emphasis on NHL patient prognosis and standard of care in front-line treatment regimens
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of the treatment and certain side effects
    • 5.1.3. Opportunities
      • 5.1.3.1. Increase in research and development of therapeutic drugs against the disease
      • 5.1.3.2. Rising investments from government and non-profit organizations
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulations for cancer treatment options
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment type: Chemotherapy treatments to prevent the spread of cancer to other parts of the body
    • 5.2.2. Application: Utilization of immunotherapy and radiation in advanced stages treatment of diffuse large B cell lymphoma (DLBCL)
    • 5.2.3. End-user: Increasing adoption of novel strategies for NHL treatment in hospitals
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Non-Hodgkin Lymphoma Treatment Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Chemotherapy
  • 6.3. Immunotherapy
  • 6.4. Radiation Therapy
  • 6.5. Stem Cell Transplantation
  • 6.6. Targeted Therapy

7. Non-Hodgkin Lymphoma Treatment Market, by Application

  • 7.1. Introduction
  • 7.2. Diffuse Large B-cell Lymphoma
  • 7.3. Follicular Lymphoma
  • 7.4. Mantle Cell Lymphoma

8. Non-Hodgkin Lymphoma Treatment Market, by End-User

  • 8.1. Introduction
  • 8.2. Cancer Centers
  • 8.3. Home Care
  • 8.4. Hospitals

9. Americas Non-Hodgkin Lymphoma Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Non-Hodgkin Lymphoma Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. EPKINLY (epcoritamab-bysp) Approved by U.S. FDA as the First and Only Bispecific Antibody to Treat Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
    • 12.3.2. Janssen Enters Worldwide Collaboration and License Agreement with Cellular Biomedicine Group to Develop Next Generation CAR-T Therapies
    • 12.3.3. Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. NON-HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. NON-HODGKIN LYMPHOMA TREATMENT MARKET DYNAMICS
  • FIGURE 7. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. NON-HODGKIN LYMPHOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. NON-HODGKIN LYMPHOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. NON-HODGKIN LYMPHOMA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DIFFUSE LARGE B-CELL LYMPHOMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DIFFUSE LARGE B-CELL LYMPHOMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY FOLLICULAR LYMPHOMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY FOLLICULAR LYMPHOMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MANTLE CELL LYMPHOMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MANTLE CELL LYMPHOMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CANCER CENTERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CANCER CENTERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 36. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 37. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 38. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 39. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 40. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 41. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 42. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 43. ARGENTINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 44. ARGENTINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 45. ARGENTINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 46. ARGENTINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 47. ARGENTINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 48. ARGENTINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 49. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 50. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 51. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 52. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 53. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 54. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 55. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 56. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 57. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 58. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 59. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 60. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 61. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 62. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 63. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 64. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 65. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 66. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 67. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 68. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 69. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 70. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 71. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 72. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 73. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 74. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 84. AUSTRALIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 85. AUSTRALIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 86. AUSTRALIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 87. AUSTRALIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 88. AUSTRALIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 89. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 90. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 91. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 92. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 93. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 94. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 95. INDIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 96. INDIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 97. INDIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 98. INDIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 99. INDIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 100. INDIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 101. INDONESIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 102. INDONESIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 103. INDONESIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 104. INDONESIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 105. INDONESIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 106. INDONESIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 107. JAPAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 108. JAPAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 109. JAPAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 110. JAPAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 111. JAPAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 112. JAPAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 113. MALAYSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 114. MALAYSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 115. MALAYSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 116. MALAYSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 117. MALAYSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 118. MALAYSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 120. PHILIPPINES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 121. PHILIPPINES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 122. PHILIPPINES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 123. PHILIPPINES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 124. PHILIPPINES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 125. SINGAPORE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 126. SINGAPORE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 127. SINGAPORE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 128. SINGAPORE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 129. SINGAPORE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 130. SINGAPORE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 132. SOUTH KOREA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 133. SOUTH KOREA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 134. SOUTH KOREA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 135. SOUTH KOREA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 136. SOUTH KOREA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 137. TAIWAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 138. TAIWAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 139. TAIWAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 140. TAIWAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 141. TAIWAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 142. TAIWAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 143. THAILAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 144. THAILAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 145. THAILAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 146. THAILAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 147. THAILAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 148. THAILAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 149. VIETNAM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 150. VIETNAM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 151. VIETNAM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 152. VIETNAM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 153. VIETNAM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 154. VIETNAM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 163. DENMARK NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 164. DENMARK NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 165. DENMARK NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 166. DENMARK NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 167. DENMARK NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 168. DENMARK NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 169. EGYPT NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 170. EGYPT NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 171. EGYPT NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 172. EGYPT NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 173. EGYPT NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 174. EGYPT NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 175. FINLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 176. FINLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 177. FINLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 178. FINLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 179. FINLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 180. FINLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 181. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 182. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 183. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 184. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 185. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 186. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 187. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 188. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 189. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 190. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 191. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 192. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 193. ISRAEL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 194. ISRAEL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 195. ISRAEL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 196. ISRAEL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 197. ISRAEL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 198. ISRAEL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 199. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 200. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 201. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 202. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 203. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 204. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 206. NETHERLANDS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 207. NETHERLANDS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 208. NETHERLANDS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 209. NETHERLANDS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 210. NETHERLANDS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 211. NIGERIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 212. NIGERIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 213. NIGERIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 214. NIGERIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 215. NIGERIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 216. NIGERIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 217. NORWAY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 218. NORWAY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 219. NORWAY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 220. NORWAY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 221. NORWAY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 222. NORWAY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 223. POLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 224. POLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 225. POLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 226. POLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 227. POLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 228. POLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 229. QATAR NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 230. QATAR NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 231. QATAR NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 232. QATAR NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 233. QATAR NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 234. QATAR NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 235. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 236. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 237. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 238. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 239. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 240. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 242. SAUDI ARABIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 243. SAUDI ARABIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 244. SAUDI ARABIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 245. SAUDI ARABIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 246. SAUDI ARABIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 248. SOUTH AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 249. SOUTH AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 250. SOUTH AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 251. SOUTH AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 252. SOUTH AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 253. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 254. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 255. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 256. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 257. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 258. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 259. SWEDEN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 260. SWEDEN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 261. SWEDEN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 262. SWEDEN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 263. SWEDEN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 264. SWEDEN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 266. SWITZERLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 267. SWITZERLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 268. SWITZERLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 269. SWITZERLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 270. SWITZERLAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 271. TURKEY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 272. TURKEY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 273. TURKEY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 274. TURKEY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 275. TURKEY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 276. TURKEY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 278. UNITED ARAB EMIRATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 279. UNITED ARAB EMIRATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 280. UNITED ARAB EMIRATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 281. UNITED ARAB EMIRATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 282. UNITED ARAB EMIRATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2023 (USD MILLION)
  • TABLE 284. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024-2030 (USD MILLION)
  • TABLE 285. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 286. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 287. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 288. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 289. NON-HODGKIN LYMPHOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 290. NON-HODGKIN LYMPHOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023